Phase I/II proof-of-principal trial of Pepscan's anti-GnRH prostate cancer vaccine in patients with hormone-refractory prostate cancer

Trial Profile

Phase I/II proof-of-principal trial of Pepscan's anti-GnRH prostate cancer vaccine in patients with hormone-refractory prostate cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2006

At a glance

  • Drugs Prostate cancer vaccine (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pepscan Therapeutics
  • Most Recent Events

    • 03 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top